On September 6, at the 2020 China International Trade in Services Fair in Beijing, the domestically-produced COVID-19 vaccine made its debut, causing concern .
The vaccines participating in the exhibition were from Sinopharm Group Sino Biotech (hereinafter referred to as “China Bio“) and Kexing Holding Biotechnology Co., Ltd. (hereinafter referred to as “Kexing“).
Currently, the two inactivated COVID-19 vaccines developed by China Biology are conducting phase III clinical trials in 10 countries including the UAE, Bahrain, Peru, Morocco, and Argentina, and are leading the world in all aspects.
China Bio’s vaccine has vaccinated 2,240 people in China in Phase I/II clinical trials, and about 50,000 people have been vaccinated in Phase III overseas, covering different populations from 115 countries and regions. “At present, 40 countries and regions have put forward emergency procurement and emergency use needs to us, and the order volume has reached more than 500 million pcs.” It is reported that the annual production capacity of its two workshops totals 300 million pcs.
Another vaccine research and development company, Kexing, said that the company’s COVID-19 inactivated vaccine is currently starting phase III clinical trials in Brazil, Indonesia and other countries and regions, and has already obtained multiple intentional orders. At the end of August, the new COVID-19 vaccine production line has been put into use and mass production has begun, with an estimated annual production capacity of more than 300 million pcs.
On-site staff introduced: “From the current domestic phase I/II clinical trials and emergency use data, our new crown inactivated vaccine is very safe.”
It is reported that the two vaccines on display will be available at the end of the year at the earliest.